BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials: Statistical evaluation of surrogate endpoints. Biom J 2016;58:104-32. [DOI: 10.1002/bimj.201400049] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Michiels S, Saad ED, Buyse M. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. Drugs 2017;77:713-9. [DOI: 10.1007/s40265-017-0728-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
2 Hendrix SB, Mogg R, Wang SJ, Chakravarty A, Romero K, Dickson SP, Sauer JM, McShane LM. Perspectives on statistical strategies for the regulatory biomarker qualification process. Biomark Med 2021;15:669-84. [PMID: 34037457 DOI: 10.2217/bmm-2020-0523] [Reference Citation Analysis]
3 Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A, Wright K, Cantrell A, Stevenson M, Palmer S. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess 2021;25:1-228. [PMID: 34990339 DOI: 10.3310/hta25760] [Reference Citation Analysis]
4 Buyse M, Burzykowski T, Saad ED. The search for surrogate endpoints for immunotherapy trials. Ann Transl Med 2018;6:231. [PMID: 30023394 DOI: 10.21037/atm.2018.05.16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Korn EL, Sachs MC, McShane LM. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer. Ann Oncol 2016;27:10-5. [PMID: 26489443 DOI: 10.1093/annonc/mdv507] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
6 Kayser S, Walter RB, Stock W, Schlenk RF. Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep 2015;10:132-44. [PMID: 25994952 DOI: 10.1007/s11899-015-0260-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
7 Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, Buyse M, Sweeney CJ, Regan MM. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. JNCI Cancer Spectr 2019;3:pkz002. [PMID: 31360890 DOI: 10.1093/jncics/pkz002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
8 Williams DR, Bürkner PC. Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis. Psychoneuroendocrinology 2017;75:141-51. [PMID: 27825069 DOI: 10.1016/j.psyneuen.2016.10.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
9 Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, Casagrande M, Ongaro E, Berretta M, Avallone A, Rosati G, Giuliani F, Fasola G. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget 2015;6:28716-30. [PMID: 26308250 DOI: 10.18632/oncotarget.4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
10 Weir CJ, Taylor RS. Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments. Pharm Stat 2022;21:740-56. [PMID: 35819121 DOI: 10.1002/pst.2219] [Reference Citation Analysis]
11 Meller M, Beyersmann J, Rufibach K. Joint modeling of progression‐free and overall survival and computation of correlation measures. Statistics in Medicine 2019;38:4270-89. [DOI: 10.1002/sim.8295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 de Jong VMT, Moons KGM, Riley RD, Tudur Smith C, Marson AG, Eijkemans MJC, Debray TPA. Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example. Res Synth Methods 2020;11:148-68. [PMID: 31759339 DOI: 10.1002/jrsm.1384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Geybels M, Wolthers BO, Kreiner FF, Rasmussen S, Bauer R. Surrogate endpoint evaluation using data from one large global randomized controlled trial. BMC Med Inform Decis Mak 2021;21:164. [PMID: 34016120 DOI: 10.1186/s12911-021-01516-8] [Reference Citation Analysis]
14 Rotolo F, Paoletti X, Michiels S. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. Comput Methods Programs Biomed 2018;155:189-98. [PMID: 29512498 DOI: 10.1016/j.cmpb.2017.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Saint-Hilary G, Barboux V, Pannaux M, Gasparini M, Robert V, Mastrantonio G. Predictive probability of success using surrogate endpoints. Stat Med 2019;38:1753-74. [PMID: 30548627 DOI: 10.1002/sim.8060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Goring S, Varol N, Waser N, Popoff E, Lozano-Ortega G, Lee A, Yuan Y, Eccles L, Tran P, Penrod JR. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis. Lung Cancer 2022;170:122-32. [PMID: 35767923 DOI: 10.1016/j.lungcan.2022.06.009] [Reference Citation Analysis]
17 Solomon A, Handels R, Wimo A, Antikainen R, Laatikainen T, Levälahti E, Peltonen M, Soininen H, Strandberg T, Tuomilehto J, Kivipelto M, Ngandu T. Effect of a Multidomain Lifestyle Intervention on Estimated Dementia Risk. J Alzheimers Dis 2021;82:1461-6. [PMID: 34151805 DOI: 10.3233/JAD-210331] [Reference Citation Analysis]
18 Baker SG. Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials. Stat Med 2018;37:507-18. [PMID: 29164641 DOI: 10.1002/sim.7561] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Sofeu CL, Emura T, Rondeau V. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints. Stat Med 2019;38:2928-42. [PMID: 30997685 DOI: 10.1002/sim.8162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sofeu CL, Rondeau V. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials. PLoS One 2020;15:e0228098. [PMID: 31990928 DOI: 10.1371/journal.pone.0228098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Flórez AJ, Molenberghs G, Van der Elst W, Alonso Abad A. An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework. Computational Statistics & Data Analysis 2022;172:107494. [DOI: 10.1016/j.csda.2022.107494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Belin L, Tan A, De Rycke Y, Dechartres A. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. Br J Cancer 2020;122:1707-14. [PMID: 32214230 DOI: 10.1038/s41416-020-0805-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Rotolo F, Paoletti X, Burzykowski T, Buyse M, Michiels S. A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. Stat Methods Med Res 2019;28:170-83. [DOI: 10.1177/0962280217718582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
24 Nadia Y, Laurie-Anne C, Xavier P. Reading, Conducting, and Developing Systematic Review and Individual Patient Data Meta-Analyses in Psychiatry for Treatment Issues. Front Psychiatry 2021;12:644980. [PMID: 34393841 DOI: 10.3389/fpsyt.2021.644980] [Reference Citation Analysis]
25 Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology 2019;157:1032-1043.e1. [PMID: 31228441 DOI: 10.1053/j.gastro.2019.06.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
26 Laporte S, Chapelle C, Bertoletti L, Ollier E, Zufferey P, Lega JC, Merah A, Décousus H, Schulman S, Meyer G, Cucherat M, Mismetti P. Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials. J Thromb Haemost 2017;15:1547-58. [PMID: 28544422 DOI: 10.1111/jth.13740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Baker SG, Kramer BS. Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening. Biomark Insights 2020;15:1177271920946715. [PMID: 32821082 DOI: 10.1177/1177271920946715] [Reference Citation Analysis]
28 Fokas E, Ströbel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, Hartmann A, Kaufmann M, Sauer R, Graeven U, Hoffmanns H, Raab HR, Hothorn T, Wittekind C, Rödel C; German Rectal Cancer Study Group. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. J Natl Cancer Inst 2017;109. [PMID: 29206996 DOI: 10.1093/jnci/djx095] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
29 Janes H, Donnell D, Gilbert PB, Brown ER, Nason M. Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. Lancet HIV 2019;6:e475-82. [PMID: 31078451 DOI: 10.1016/S2352-3018(19)30133-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
30 Huang Y. Binary surrogates with stratified samples when weights are unknown. Comput Stat 2019;34:653-82. [DOI: 10.1007/s00180-018-0838-3] [Reference Citation Analysis]
31 Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C, Sauer R, Kaufmann M, Hothorn T, Rödel C; German Rectal Cancer Study Group. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol 2018;29:1521-7. [PMID: 29718095 DOI: 10.1093/annonc/mdy143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
32 Mokhtarzadeh A, Hassanpour S, Vahid ZF, Hejazi M, Hashemi M, Ranjbari J, Tabarzad M, Noorolyai S, de la Guardia M. Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers. J Control Release 2017;266:166-86. [PMID: 28941992 DOI: 10.1016/j.jconrel.2017.09.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
33 Hartung EA. Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol 2016;31:381-91. [PMID: 25980469 DOI: 10.1007/s00467-015-3104-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
34 Bovbjerg ML, Cheyney M. Current Resources for Evidence-Based Practice, July 2020. J Obstet Gynecol Neonatal Nurs 2020;49:391-404. [PMID: 32574584 DOI: 10.1016/j.jogn.2020.06.002] [Reference Citation Analysis]
35 Burzykowski T. Semi-parametric accelerated failure-time model: A useful alternative to the proportional-hazards model in cancer clinical trials. Pharm Stat 2021. [PMID: 34553482 DOI: 10.1002/pst.2169] [Reference Citation Analysis]
36 Williams S. Surrogate endpoints in early prostate cancer research. Transl Androl Urol 2018;7:472-82. [PMID: 30050805 DOI: 10.21037/tau.2018.05.10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
37 Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value Health 2017;20:487-95. [PMID: 28292495 DOI: 10.1016/j.jval.2016.10.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
38 Bovbjerg ML, Dissanayake MV, Cheyney M, Brown J, Snowden JM. Utility of the 5-Minute Apgar Score as a Research Endpoint. Am J Epidemiol 2019;188:1695-704. [PMID: 31145428 DOI: 10.1093/aje/kwz132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
39 Emura T, Sofeu CL, Rondeau V. Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials. Stat Methods Med Res 2021;30:2634-50. [PMID: 34632882 DOI: 10.1177/09622802211046390] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Roselló S, Cervantes A. Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points. Annals of Oncology 2018;29:1493-4. [DOI: 10.1093/annonc/mdy182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020;21:e252-64. [PMID: 32359501 DOI: 10.1016/S1470-2045(20)30024-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
42 Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood 2018;131:955-62. [PMID: 29255066 DOI: 10.1182/blood-2017-06-792333] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
43 Fiteni F, Westeel V, Bonnetain F. Surrogate endpoints for overall survival in lung cancer trials: a review. Expert Review of Anticancer Therapy 2017;17:447-54. [DOI: 10.1080/14737140.2017.1316196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
44 Aronson JK, Ferner RE. Biomarkers-A General Review. Curr Protoc Pharmacol. 2017;76:9.23.1-9.23.17. [PMID: 28306150 DOI: 10.1002/cpph.19] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
45 Leverkus F, Chuang-Stein C. Implementation of AMNOG: An industry perspective. Biom J 2016;58:76-88. [PMID: 26332597 DOI: 10.1002/bimj.201300256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Kuroki M, Shingaki R, Qu Y. Proportion of treatment effect mediated by surrogate endpoints. Biom J 2021;63:105-21. [PMID: 33200481 DOI: 10.1002/bimj.202000119] [Reference Citation Analysis]
47 Zhao S, Zhang Z, Zhang Y, Hong S, Zhou T, Yang Y, Fang W, Zhao H, Zhang L. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. Int J Cancer 2019;144:2854-66. [PMID: 30430561 DOI: 10.1002/ijc.31995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]